Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12


Impact of Locally Administered Carboxydextran-Coated Super-Paramagnetic Iron Nanoparticles on Cellular Immune Function.

Pedro L, Harmer Q, Mayes E, Shields JD.

Small. 2019 May;15(20):e1900224. doi: 10.1002/smll.201900224. Epub 2019 Apr 15.


Lymphatics: at the interface of immunity, tolerance, and tumor metastasis.

Shields JD.

Microcirculation. 2011 Oct;18(7):517-31. doi: 10.1111/j.1549-8719.2011.00113.x. Review.


Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21.

Shields JD, Kourtis IC, Tomei AA, Roberts JM, Swartz MA.

Science. 2010 May 7;328(5979):749-52. doi: 10.1126/science.1185837. Epub 2010 Mar 25.


Transmural flow modulates cell and fluid transport functions of lymphatic endothelium.

Miteva DO, Rutkowski JM, Dixon JB, Kilarski W, Shields JD, Swartz MA.

Circ Res. 2010 Mar 19;106(5):920-31. doi: 10.1161/CIRCRESAHA.109.207274. Epub 2010 Feb 4.


Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype.

Issa A, Le TX, Shoushtari AN, Shields JD, Swartz MA.

Cancer Res. 2009 Jan 1;69(1):349-57. doi: 10.1158/0008-5472.CAN-08-1875.


Autologous chemotaxis as a mechanism of tumor cell homing to lymphatics via interstitial flow and autocrine CCR7 signaling.

Shields JD, Fleury ME, Yong C, Tomei AA, Randolph GJ, Swartz MA.

Cancer Cell. 2007 Jun;11(6):526-38.


Cooperative and redundant roles of VEGFR-2 and VEGFR-3 signaling in adult lymphangiogenesis.

Goldman J, Rutkowski JM, Shields JD, Pasquier MC, Cui Y, Schmökel HG, Willey S, Hicklin DJ, Pytowski B, Swartz MA.

FASEB J. 2007 Apr;21(4):1003-12. Epub 2007 Jan 8. Erratum in: FASEB J. 2007 Jun;21(8):1942.


Chemokine-mediated migration of melanoma cells towards lymphatics--a mechanism contributing to metastasis.

Shields JD, Emmett MS, Dunn DB, Joory KD, Sage LM, Rigby H, Mortimer PS, Orlando A, Levick JR, Bates DO.

Oncogene. 2007 May 10;26(21):2997-3005. Epub 2006 Nov 27.


VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression.

Woolard J, Wang WY, Bevan HS, Qiu Y, Morbidelli L, Pritchard-Jones RO, Cui TG, Sugiono M, Waine E, Perrin R, Foster R, Digby-Bell J, Shields JD, Whittles CE, Mushens RE, Gillatt DA, Ziche M, Harper SJ, Bates DO.

Cancer Res. 2004 Nov 1;64(21):7822-35.


Lymphatic density and metastatic spread in human malignant melanoma.

Shields JD, Borsetti M, Rigby H, Harper SJ, Mortimer PS, Levick JR, Orlando A, Bates DO.

Br J Cancer. 2004 Feb 9;90(3):693-700.


Functional significance of MMP-2 and MMP-9 expression by human malignant oral keratinocyte cell lines.

Robinson CM, Stone AM, Shields JD, Huntley S, Paterson IC, Prime SS.

Arch Oral Biol. 2003 Nov;48(11):779-86.


VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma.

Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD, Peat D, Gillatt D, Harper SJ.

Cancer Res. 2002 Jul 15;62(14):4123-31.

Supplemental Content

Loading ...
Support Center